Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Liposarcoma × Pioglitazone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4 Leukoplakia, Oral 2 Carcinoma, Non-Small-Cell Lung 2 Skin Neoplasms 1 Prostatic Neoplasms 1 Polycystic Ovary Syndrome 1 Pancreatic Neoplasms 1 Lung Neoplasms 1 Liposarcoma, Myxoid 1 Liposarcoma 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Acute 1 Insulin Resistance 1 Head and Neck Neoplasms 1 Carotid Intimal Medial Thickness 1 1 Carcinoma, Squamous Cell 1 Breast Neoplasms 1

Interventions

Trabectedin 5 Doxorubicin 5 pazopanib 3 Radiotherapy 3 Gemcitabine 3 ribociclib 2 palbociclib 2 brostallicin 2 Sunitinib 2 Imatinib Mesylate 2 Docetaxel 2 Dexamethasone 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 zimberelimab 1 temsirolimus 1 tanespimycin 1 talimogene laherparepvec 1 sotigalimab 1 soblidotin 1 sitravatinib 1 saracatinib 1 ridaforolimus 1 regorafenib 1 plitidepsin 1 perifosine 1 pembrolizumab 1 liposomal doxorubicin 1 exatecan 1 eribulin 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04794127 2026-02-18

TRABEPIO

Mario Negri Institute for Pharmacological Research

Phase 2 Completed

Liposarcoma, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡